XML 43 R32.htm IDEA: XBRL DOCUMENT v3.25.3
STOCKHOLDERS’ EQUITY (DEFICIT) (Tables)
 9 Months Ended
Sep. 30, 2025
Accumulated Other Comprehensive Income (Loss) [Line Items]  
SCHEDULE OF RESERVED SHARES

 

      
Exercise of issued and future grants of stock options   15,114 
Conversion of Series A-2 preferred stock   267,364 
Conversion of Series A-3 preferred stock   2,003,562 
Conversion of Series B preferred stock   17,784,061 
Conversion of convertible debt   58,771 
Exercise of stock warrants   579,575 
 Total   20,708,447 
SCHEDULE OF OUTSTANDING PREFERRED STOCK

 

  

Authorized

Shares

  

Outstanding

Shares

   Conversion Price  

Common Stock

Equivalent

 
Series A-2   10,000    601   $2.246    267,364 
Series A-3   10,000    4,500   $2.246    2,003,562 
Series B   500,000    39,943   $2.246    17,784,061 
SCHEDULE OF STOCK OPTION ACTIVITY

The following represents a summary of the options granted to employees and non-employee service providers that were outstanding at September 30, 2025, and changes during the nine-month period then ended:

 

   Shares   Weighted–
Average
Exercise
Price		   Range of
Exercise
Price		   Weighted–
Average
Remaining
Life (Years)		 
Total outstanding – December 31, 2024   1,870   $1,948.41   $256.80 — $2,565.00     5.93 
Granted   —    —    —    — 
Expired   —    —    —    — 
Forfeited   (300)  $1,527.27   $256.80 — $2,565.00     — 
Total outstanding – September 30, 2025   1,570   $2,028.88   $256.80 — $2,485.00     5.11 
Exercisable (vested)   1,560   $2,040.24   $256.80 — $2,485.00     5.09 
Non-Exercisable (non-vested)   10   $256.80   $256.80 — $256.80     7.02 

 

The following represents a summary of the options granted to employees and non-employee service providers that were outstanding at September 30, 2024, and changes during the nine-month period then ended:

 

      Weighted–      Weighted– 
       Average   Range of   Average 
       Exercise   Exercise   Remaining 
   Shares   Price   Price   Life (Years) 
Total outstanding – December 31, 2023   7,978   $1,760.26   $ 256.80 — $2,565.00    7.06 
Granted   —    —    —    — 
Expired   —    —    —    — 
Forfeited   (1,239)  $743.77   $256.80 — $2,565.00    — 
Total outstanding – September 30, 2024   6,739   $1,947.06   $256.80 — $2,565.00    6.22 
Exercisable (vested)   6,153   $2,103.52   $256.80 — $2,565.00    6.08 
Non-Exercisable (non-vested)   586   $305.69   $256.80 — $620.00    7.71 
SCHEDULE OF SHARE-BASED COMPENSATION EXPENSE

The Company recorded share-based compensation expense and classified it in the unaudited condensed consolidated statements of operations as follows:

 

   2025   2024   2025   2024 
   For the Three Months Ended
September 30,		   For the Nine Months Ended
September 30,		 
   2025   2024   2025   2024 
General and administrative  $—   $27,208   $269   $94,264 
Research and development   —    —    —    24,680 
Total  $—   $27,208   $269   $118,944 
Compensatory Warrant Activity [Member]  
Accumulated Other Comprehensive Income (Loss) [Line Items]  
SCHEDULE OF NON COMPENSATORY WARRANT ACTIVITY

The following table summarizes the equity classified compensatory warrant activity for the nine months ended September 30, 2025:

 

    Common Stock  
    Shares    Weighted–Average
Exercise
Price		    Range of
Exercise Price		    Weighted–
Average
Remaining
Life (Years)		 
Total outstanding – December 31, 2024   509   $1,270.25    $1,270.25 — $1,270.25    0.69 
Exercised   —    —    —    — 
Expired   (349)  $1,270.25    $1,270.25 — $1,270.25    — 
Forfeited   —    —    —    — 
Total outstanding – September 30, 2025   160   $1,270.25    $1,270.25— $1,270.25    1.06 
Exercisable   160   $1,270.25    $1,270.25 — $1,270.25    1.06 
Non-Exercisable   —    —    —    — 

 

The following table summarizes the equity classified compensatory warrant activity for the nine months ended September 30, 2024:

 

   Shares   Weighted–Average
Exercise
Price		   Range of
Exercise Price		   Weighted–
Average
Remaining
Life (Years)		 
Total outstanding – December 31, 2023   2,381   $534.44    $66.00 — $1,270.25    1.25 
Exercised   —    —    —    — 
Expired   (520)  $1,033.15    $1,033.15 — $1,033.15    — 
Forfeited   —    —    —    — 
Total outstanding – September 30, 2024   1,861   $351.88    $6.50 — $1,270.25    4.50 
Exercisable   1,861   $351.88    $6.50 — $1,270.25    0.72 
Non-Exercisable   —    —    —    — 
Non Compensatory Warrant Activity [Member]  
Accumulated Other Comprehensive Income (Loss) [Line Items]  
SCHEDULE OF NON COMPENSATORY WARRANT ACTIVITY

The following table summarizes the noncompensatory equity classified warrant activity for the nine months ended September 30, 2025:

 

   Common Stock 
   Shares   Weighted–
Average
Exercise
Price		   Range of
Exercise Price		   Weighted–
Average
Remaining
Life (Years)		 
Total outstanding – December 31, 2024   72,004   $6.50    $6.50 — $6.50     3.99 
Granted   1,087,266    2.47    $2.47 — $2.47    5.00 
Exercised   —    —    —    — 
Expired   —    —    —    — 
Forfeited   —    —    —    — 
Total outstanding – September 30, 2025   1,159,270   $2.72    $2.47 — $6.50     4.89 
Exercisable   1,159,270   $2.72    $2.47 — $6.50     4.89 
Non-Exercisable   —    —    —    — 

 

 

The following table summarizes the noncompensatory equity classified warrant activity for the nine months ended September 30, 2024:

 

   Common Stock 
   Shares   Weighted–
Average
Exercise
Price		   Range of
Exercise Price		   Weighted–
Average
Remaining
Life (Years)		 
Total outstanding – December 31, 2023   50,141   $36.50    $36.50 — $36.50     4.47 
Granted   70,021   $6.81    $6.50 — $7.80     4.54 
Pre-funded investor warrants issued   239,456   $0.05    $0.05 — $0.05     n/a  
Exercised   (31,998)  $13.00    $13.00 — $13.00     — 
Reclassified to liabilities   (2,314)  $6.50    $6.50 — $6.50     4.41 
Expired   —    —    —    — 
Forfeited   —    —    —    — 
Total outstanding – September 30, 2024   325,306   $6.50    $0.00 — $6.50     n/a 
Exercisable   309,287   $6.50    $0.00 — $6.50     n/a 
Non-Exercisable   16,019   $7.80    $7.80 — $7.80     4.94